MNPR
NASDAQ · Biotechnology
Monopar Therapeutics Inc
$55.21
-3.46 (-5.90%)
Financial Highlights (FY 2025)
Revenue
251.96M
Net Income
-49,856,785
Gross Margin
28.6%
Profit Margin
-19.8%
Rev Growth
+2.3%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 28.6% | 28.6% | 28.6% |
| Operating Margin | -29.6% | -29.0% | -25.2% |
| Profit Margin | -19.8% | -20.2% | -22.8% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 251.96M | 240.93M | 249.50M |
| Gross Profit | 72.16M | 69.00M | 71.45M |
| Operating Income | -74,563,284 | -69,811,757 | -62,807,947 |
| Net Income | -49,856,785 | -48,544,141 | -56,777,530 |
| Gross Margin | 28.6% | 28.6% | 28.6% |
| Operating Margin | -29.6% | -29.0% | -25.2% |
| Profit Margin | -19.8% | -20.2% | -22.8% |
| Rev Growth | +2.3% | +24.0% | -9.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 69.96M | 65.30M | 73.37M |
| Total Equity | 275.48M | 281.04M | 268.03M |
| D/E Ratio | 0.25 | 0.23 | 0.27 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -96,691,861 | -80,803,710 | -82,101,366 |
| Free Cash Flow | -37,656,070 | -41,639,536 | -51,685,705 |